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that they draw attention to the diffi  culties 
in deciding whether hypercellularity in 
Bowman ’ s space represents a true crescent 
or proliferation of parietal epithelial 
cells — this may confound attempts to 
assess the prognostic signifi cance of ext-
racapillary proliferation. 
 Th ere are some points that will need to be 
addressed in further studies. Firstly, as is 
noted above, the authors attempt to make 
the distinction between a post-infl amma-
tory scar and an area of what they would 
call  ‘ true ’ FSGS on the basis of the presence 
of hyalinosis lesions and / or epithelial hyper-
plasia. However, they do not provide evi-
dence that these are valid criteria for making 
the distinction. Secondly, as they admit, 
they do not show that there is agreement 
between diff erent pathologists in classifying 
the diff erent types of FSGS. Th irdly, since 
their criteria for the cellular form of FSGS 
require the presence of endocapillary hyper-
cellularity, it is clear that these biopsies 
would have been scored in the Oxford clas-
sifi cation as E1, and so further analysis will 
be necessary to ask how this should be 
incorporated into the Oxford schema. 
Finally, as they themselves point out, 80 % of 
their biopsies showed some form of FSGS, 
which is a higher proportion than previ-
ously reported. Th us, their results will need 
to be validated in other groups of patients. 
 In conclusion, these papers 3,4 should 
make us reconsider the signifi cance of 
segmental sclerosis in IgA nephropathy. It 
is likely that there are at least three ways 
that segmental sclerosis may occur in 
glomeruli in IgA nephropathy ( Figure 1 ): 
firstly, by post-inflammatory scarring; 
secondly, due to compensatory hemody-
namic changes following loss of nephrons; 
and thirdly, as these papers emphasize, by 
primary podocyte damage, perhaps sec-
ondary to mediators released from 
mesangial cells. If a signifi cant percentage 
of segmental sclerotic lesions represent 
the consequence of primary podocyte 
damage, it may lead us to consider new 
pathogenic mechanisms and may also 
have therapeutic consequences. In addi-
tion, we may need to refi ne the way in 
which we assess segmental sclerosis in 
determining the prognostic implications 
of histology. It is reassuring that the stud-
ies reported here support the conclusions 
of the Oxford classifi cation, but they raise 
the possibility that the utility of the 
classifi cation could be further enhanced 
by the distinguishing of diff erent types of 
segmental sclerosis. Th at possibility will 
require confirmation of the results in 
other larger cohorts. 
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 BACKGROUND 
 Th e clinical management of patients 
with circulating alloantibodies in  renal 
transplantation is almost exclusively 
 focused on antibodies against ABO 
blood group antigens and the  human 
leukocyte antigen (HLA) system. 
Th ere is solid and universally accepted 
evidence for an important role of anti-
HLA antibodies in both early / acute 
and late / chronic rejection of renal allo-
graft s. We now possess a number of 
diff erent cell-based assays (cytotoxic or 
fl ow cyto metric cross-match) and solid-
phase assays (enzyme-linked immuno-
sorbent assay, HLA-coated beads) that 
reliably detect poten tially alloreac-
tive antibodies ( Figure 1 ). Th e recently 
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 developed solid-phase assays signifi -
cantly improved the sensitivity of anti-
body detection and also permit the pre-
cise defi nition of antigen specifi city, but 
they are almost exclusively restricted to 
the HLA system. 
 DONOR-REACTIVE ANTIBODIES MIGHT 
BE DIRECTED AT NON-HLA ANTIGENS 
 Well-documented cases of antibody-
mediated rejection (AMR) of allograft s 
from HLA-identical siblings suggest 
that non-HLA antibodies might also 
cause allograft  injury and loss. 1 Th is 
concept was further supported by a 
systematic analysis of registry data that 
surprisingly revealed that panel-reactive 
antibodies (PRAs) adversely aff ected 
outcome even in recipients of kidneys 
from HLA- identical sibling donors. If 
PRAs (detected by lymphocytotoxic-
ity assays) were directed only against 
HLA antigens, they should not bind 
to a fully HLA-matched graft  and thus 
should not aff ect outcome. Th e reduced 
graft   survival in PRA- positive recipi-
ents of HLA- identical graft s therefore 
might indicate the presence and clini-
cal relevance of non-HLA antibodies. 2 
Moreover, several antigens expressed on 
endothelial cells (ECs) have been iden-
tifi ed as putative targets of non-HLA 
antibodies (recently reviewed by Zhang 
and Reed 3 ). So far the evidence for 
non-HLA antibodies causing rejection, 
however, remains largely circumstantial. 
Th is is unlikely to change until validated 
screening assays for direct detection of 
non-HLA antibodies become available. 
In the past, several diff erent approaches 
were taken to detect and further defi ne 
non-HLA antibodies: 
 (1)  various preparations of ECs as sub-
strate for antibody screening assays; 
 (2)  proteomic approaches using protein 
extracts from diff erent sources (cell 
lysates, protein microarrays) for 
antibody screening and identifi ca-
tion of specifi cities; 
 (3)  targeted searching for antibodies 
with defi ned specifi cities (major 
histocompatibility complex class I 
polypeptide-related sequence A 
(MICA), angiotensin II type 1 
receptor, glutathione- S -transferase 
T1 (GSTT1)). 
 With the exception of MICA testing, 
no diagnostic assays suitable for clini-
cal diagnostics had been commercially 
available until recently. Th is is espe-
cially true for the screening tests for 
anti- endothelial cell antibodies (AE-
CAs): many diff erent, almost exclusively 
custom-made assays using various EC 
preparations from diff erent sources had 
been used in the past. 
 ENDOTHELIAL CELLS MIGHT BE AN 
IDEAL SUBSTRATE FOR  IN VITRO 
DETECTION OF NON-HLA ANTIBODIES 
 In a new study, Sun and colleagues 4 (this 
issue) also used ECs as substrate for the 
detection of non-HLA  antibodies. Th eir 
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 Figure 1  |  Assays for alloreactive antibodies. Ab, antibody; CDC, complement-dependent cytotoxicity; ELISA, enzyme-linked immunosorbent 
assay; HLA, human leukocyte antigen; IF, immunofluorescence; PRA, panel-reactive antibody.  * In combination with anti-HLA antibody assays.   †  Can be 
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assay is based on the immuno fl uorescent 
detection of recipient anti bodies bound 
to human umbilical vein ECs (HUVECs) 
immobilized to glass slides. Th is strat-
egy is not novel but is quite reasonable, 
as ECs are the prime targets in AMR, 
and they express various antigens that 
are not present on lymphocytes used in 
clinically established antibody detection 
assays. Th e use of a commercially avail-
able HUVEC preparation and antibody 
detection system (Titerplane, EUROIM-
MUN) sets this study apart from most 
previous studies that also used ECs as 
substrate for antibody screening. In this 
study, both pre- and post-transplantation 
serum samples were assayed for AECAs. 
No adverse impact on graft  function was 
observed with AECAs detected before 
transplantation, but the authors found 
that  de novo AECAs (appearing aft er 
transplantation in previously AECA-
negative patients) were associated with a 
higher risk of steroid-resistant rejection 
episodes and early rejections, while the 
overall incidence of rejection was not dif-
ferent between the groups. Interestingly, 
biopsies in AECA-positive patients, de-
spite the absence of C4d in the major-
ity of cases, commonly showed signs 
of microvascular injury similar to what 
can be observed in  ‘ classical ’ C4d-pos-
tive AMR due to anti-HLA antibodies. 
Allograft  survival and graft  function at 
3 years were slightly inferior in patients 
with  de novo AECAs as compared with 
the consistently AECA-negative control 
group. Th e authors therefore conclude 
that AECAs may have a pathogenic eff ect 
and are directed against non-HLA anti-
gens. Th is is an interesting concept and 
might provide a rationale for applying 
the assay presented here at least to pa-
tients with morphological signs of AMR 
 (microvascular injury) in the absence of 
detectable anti-HLA antibodies. 
 WHAT ARE THE TARGETS OF ANTI-
ENDOTHELIAL CELL ANTIBODIES? 
 Th e non-HLA specifi city of AECAs was 
assumed but not thoroughly investigat-
ed in this study, which, however, was not 
designed to identify potential antigenic 
targets beyond the HLA system. On the 
basis of the data presented in this study, 
it cannot be excluded that at least some 
AECAs are due to anti-HLA reactivity, 
as nine patients of the AECA-positive 
cohort developed PRAs aft er transplan-
tation. It is not mentioned how many of 
these patients belonged to the  de novo 
AECA group ( n  =  22) or whether and 
how the presence of PRAs was related 
to rejection, C4d positivity, or outcome. 
It would be necessary to match the HLA 
expression profi le of ECs with the HLA 
specifi city of sera (determined by sin-
gle-antigen Luminex or FlowPRA test-
ing) in order to identify or exclude HLA 
antibodies reactive with ECs. An inher-
ent problem of the test system used in 
this study is the unknown HLA pro-
fi le of HUVECs. Th e strategy outlined 
above for identifying anti-HLA AECAs 
could thus not have been applied at all. 
 Another crucial issue is donor specifi -
city of antibodies (both HLA and non-
HLA specifi cities), as this information is 
required for estimation of the risk of 
AMR, based on the respective HLA 
expression profi le of the donor. Th is infor-
mation could, on the one hand, derive 
from donor-specific endothelial-cell 
cross-match (ECXM) testing, which to my 
knowledge has not yet been performed in 
kidney transplantation, or could possibly 
also be deduced from the identifi cation of 
specific antigenic targets of non-HLA 
AECAs. As identifi cation of antigens was 
not the goal of this study and the technol-
ogy used does not permit conclusions 
about the nature of target antigens on 
HUVECs, this matter could not be 
addressed. It is, however, remarkable that 
antibody binding consistently resulted in 
a coarsely granular perinuclear cytoplas-
mic staining pattern. On the basis of the 
experience with HLA antibodies, one 
would expect a labeling of the cell mem-
brane, since surface antigens exposed to 
the bloodstream are the most likely anti-
genic targets for circulating antibodies (as 
is also evidenced by the outstanding 
importance of blood group antigens and 
the HLA system in allograft  rejection). 
It is, however, also possible that the 
uniformly granular staining pattern does 
not really indicate antibody specifi city for 
a cytoplasmic target but rather results 
from the processing of cells by fi xation or 
other kinds of chemical treatment. Th is 
might be an important issue because 
cross-linking fi xation (as achieved with 
the widely used formaldehyde-based 
fi xatives) might lead to a profound altera-
tion of antigenic target structures and 
thereby lead to false-negative or even 
false-positive (background) staining. 
 HOW TO DETECT DONOR-SPECIFIC OR 
AUTOREACTIVE ANTI-ENDOTHELIAL 
CELL ANTIBODIES 
 Th e identifi cation of a potential donor 
specifi city of antibodies or the discrimi-
nation of alloreactive from autoreactive 
antibodies was beyond the scope of this 
study. Knowledge of these properties of 
antibodies is, however, crucial for risk 
assessment in AECA-positive  patients, 
as certain types of anti-endothelial 
 autoantibodies can also be present in 
healthy individuals and do not appear 
to be  necessarily pathogenic. 5 A true 
donor- specifi c ECXM would provide 
much of this information, especially 
if complemented with testing of auto-
logous ECs. Isolating ECs from donors 
and recipients is technically possible but 
far too  complex and expensive for any 
regular diagnostic application. To my 
knowledge, there is only one published 
report on donor-specifi c ECXM testing 
in heart transplantation, 6 and so far no 
studies on donor-derived ECs exist for 
the kidney. 
 An interesting approach to achieving a 
donor-specific ECXM was introduced 
some years ago 7 and resulted in the develop-
ment of a commercially available flow 
cytometric assay (XM-ONE, AbSorber) 8 
that was recently validated in a multicenter 
trial. 9 Th is test is based on putative EC pre-
cursor cells isolated from peripheral blood. 
This method also offers the attractive 
option of also performing the test on recip-
ient cells in order to discriminate between 
alloantibodies and autoantibodies. Th e 
validation trial revealed several patients 
with postive ECXM in the absence of HLA 
antibodies who developed features of AMR 
aft er transplantation, again suggesting a 
pathogenic role for non-HLA AECAs. 9 
The new assay, however, also has some 
important limitations: 
 (1)  It is not clear whether circulating 
precursor ECs refl ect the proper-
ties of graft  ECs. Notably, precursor 
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ECs isolated with the XM-ONE kit 
lack some important EC markers, 
such as CD31 and CD34. 7 
 (2)  It was observed that some sera 
 showing antibody binding 
 signifi cantly below control values 
(negative  channel shift  on fl ow 
cytometry) turned positive aft er 
dilution of the serum sample. 
Th is paradoxical result could not 
be convincingly explained. 
 (3)  Post-transplantation testing 
would require expensive and 
time- consuming cryopreservation 
of donor cells, which is not current 
practice in most centers. 
 CONCLUSION 
 Mostly indirect evidence suggests an 
important pathogenic role for non-
HLA AECAs in both acute and chronic 
 rejection. Th e lack of standardized detec-
tion assays, however, hampers the sys-
tematic collection of data in multicenter 
trials. Diagnostic tests such as the one by 
Sun  et al. 4 that are based on commercial-
ly available platforms could pave the way 
for testing larger patient populations but 
suff er from some important limitations. 
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